Drug intelligence / Profile preview

Adderall

Development stage
Approved
Lead developer
Takeda
Modality
Small Molecules
Administration
Oral
01

Overview

Adderall is a central nervous system (CNS) stimulant composed of a combination of four amphetamine salts: dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine aspartate monohydrate, and amphetamine sulfate. It is primarily indicated for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. The medication works by increasing the levels of norepinephrine and dopamine in the synaptic cleft through the inhibition of reuptake and the promotion of release via the dopamine transporter (DAT) and norepinephrine transporter (NET). It also acts as an agonist at the trace amine-associated receptor 1 (TAAR1) and inhibits the vesicular monoamine transporter 2 (VMAT2). While widely used as a prescription medication, it was the subject of a Phase 4 clinical trial by the Mayo Clinic (NCT02979327) to evaluate its acute cardiovascular effects, such as changes in blood pressure and heart rate, in healthy adults.

Brand names
AdderallAdderall XRMydayis
Other names
mixed amphetamine saltsMASamphetamine saltsamphetamine + dextroamphetamine
02

Targets

DAT (Dopamine plasma membrane transport protein)TAAR1 (Trace amine-associated receptor 1)NET (Norepinephrine Transporter)VMAT2 (Vesicular monoamine transporter 2)MAOB (Monoamine oxidase B)MAOA (Monoamine oxidase A)

Beyond the preview

Go deeper on Adderall.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Adderall.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call